{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T04:07:48Z","timestamp":1746331668602,"version":"3.40.4"},"reference-count":55,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"21","license":[{"start":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T00:00:00Z","timestamp":1716508800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2024,5,24]]},"abstract":"<jats:sec>\n            <jats:title>Background:<\/jats:title>\n            <jats:p>We aimed to compare 7 newer immunotherapies and targeted therapies for platinum-resistant relapsed ovarian cancer.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods:<\/jats:title>\n            <jats:p>We conducted a comprehensive search of PubMed, EMBASE, and Cochrane Library electronic databases for phase III trials involving platinum-resistant recurrent ovarian cancer (PRrOC) patients treated with immunotherapy or targeted therapy in combination with chemotherapy. The quality of the included trials was assessed using the GRADE method. The primary outcome of comparison was progression-free survival, and secondary outcomes included overall survival and safety.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results:<\/jats:title>\n            <jats:p>This analysis included 7 randomized phase III controlled trials, encompassing 2485 PRrOC patients. Combining bevacizumab plus chemotherapy and lurbinectedin demonstrated statistically significant differences in progression-free survival compared to all other regimens of interest. However, no statistically significant differences were observed in the overall survival. Nivolumab and mirvetuximab exhibited fewer serious adverse events than the other regimens of interest.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Conclusions:<\/jats:title>\n            <jats:p>Our findings indicate that bevacizumab combined with chemotherapy and lurbinectedin monotherapy has significant efficacy in patients with PRrOC. For patients with PRrOC who have exhausted treatment options, nivolumab and mirvetuximab may be considered as alternatives because of their better safety profiles.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/md.0000000000038183","type":"journal-article","created":{"date-parts":[[2024,5,24]],"date-time":"2024-05-24T18:02:21Z","timestamp":1716573741000},"page":"e38183","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Comparison of target agent treatment strategies for platinum-resistant recurrent ovarian cancer: A Bayesian network meta-analysis"],"prefix":"10.1097","volume":"103","author":[{"given":"John Hang","family":"Leung","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Ditmanson Medical Foundation Chia-Yi Christian Hospital, Chia-Yi, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henry W. C.","family":"Leung","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, An-Nan Hospital, China Medical University, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shyh-Yau","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Radiation, An-Nan Hospital, China Medical University, Tainan, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hei-Tung","family":"Yip Fion","sequence":"additional","affiliation":[{"name":"Department Management Office for Health Data, Clinical Trial Research Center, China Medical University Hospital, Taichung, Taiwan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Agnes L. F.","family":"Chan","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, An-Nan Hospital, China Medical University, Tainan, Taiwan."}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250504","doi-asserted-by":"crossref","first-page":"209","DOI":"10.3322\/caac.21660","article-title":"Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"R2-20250504","article-title":"Health Promotion Administration."},{"key":"R3-20250504","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1001\/jama.2017.21421","article-title":"Screening for ovarian cancer: updated evidence report and systematic review for the US Preventive Services Task Force.","volume":"319","author":"Henderson","year":"2018","journal-title":"JAMA"},{"key":"R4-20250504","doi-asserted-by":"crossref","first-page":"e66","DOI":"10.3802\/jgo.2018.29.e66","article-title":"Artificial intelligence weights the importance of factors predicting complete cytoreduction at secondary cytoreductive surgery for recurrent ovarian cancer.","volume":"29","author":"Bogani","year":"2018","journal-title":"J Gynecol Oncol"},{"key":"R5-20250504","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1016\/S0140-6736(18)32552-2","article-title":"Epithelial ovarian cancer.","volume":"393","author":"Lheureux","year":"2019","journal-title":"Lancet"},{"issue":"Suppl 4","key":"R6-20250504","doi-asserted-by":"crossref","first-page":"iv259","DOI":"10.1093\/annonc\/mdy157","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.","volume":"29","author":"Ledermann","year":"2018","journal-title":"Ann Oncol"},{"issue":"suppl_8","key":"R7-20250504","doi-asserted-by":"crossref","first-page":"viii13","DOI":"10.1093\/annonc\/mdx446","article-title":"Acquired chemotherapy resistance in ovarian cancer.","volume":"28","author":"Christie","year":"2017","journal-title":"Ann Oncol"},{"issue":"Suppl 24","key":"R8-20250504","doi-asserted-by":"crossref","first-page":"4609","DOI":"10.1002\/cncr.32500","article-title":"Treatment of recurrent epithelial ovarian cancer.","volume":"125","author":"Pignata","year":"2019","journal-title":"Cancer"},{"key":"R9-20250504","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1200\/JCO.2013.51.4489","article-title":"Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: the AURELIA open-label randomized phase III trial.","volume":"32","author":"Pujade-Lauraine","year":"2014","journal-title":"J Clin Oncol"},{"key":"R10-20250504","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/j.annonc.2021.02.017","article-title":"Phase III, randomized trial of mirvetuximab soravtansine versus chemotherapy in patients with platinum-resistant ovarian cancer: primary analysis of FORWARD I.","volume":"32","author":"Moore","year":"2021","journal-title":"Ann Oncol"},{"key":"R11-20250504","doi-asserted-by":"crossref","first-page":"831612","DOI":"10.3389\/fonc.2022.831612","article-title":"Preclinical and clinical evidence of lurbinectedin in ovarian cancer: current status and future perspectives.","volume":"12","author":"Musacchio","year":"2022","journal-title":"Front Oncol"},{"key":"R12-20250504","doi-asserted-by":"crossref","first-page":"n71","DOI":"10.1136\/bmj.n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"R13-20250504","doi-asserted-by":"crossref","first-page":"l4898","DOI":"10.1136\/bmj.l4898","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials.","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"R14-20250504","article-title":"National cancer society common terminology criteria for adverse events, Version 5.0."},{"key":"R15-20250504","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1186\/2046-4053-3-110","article-title":"Microsoft-excel-based tool for running and critically appraising network meta-analyses\u2013an over view and application of NetMetaXL.","volume":"3","author":"Brown","year":"2014","journal-title":"Syst Rev"},{"key":"R16-20250504","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1177\/0272989X12455847","article-title":"Evidence synthesis for decision making 4: inconsistency in networks of evidence based on randomized controlled trials.","volume":"33","author":"Dias","year":"2013","journal-title":"Med Decis Making"},{"key":"R17-20250504","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1200\/JCO.2015.66.0787","article-title":"Double-blind, placebo-controlled, randomized phase III trial evaluating pertuzumab combined with chemotherapy for low tumor human epidermal growth factor receptor 3 mRNA-expressing platinum-resistant ovarian cancer (PENELOPE).","volume":"34","author":"Kurzeder","year":"2016","journal-title":"J Clin Oncol"},{"key":"R18-20250504","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/S1470-2045(21)00216-3","article-title":"Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.","volume":"22","author":"Pujade-Lauraine","year":"2021","journal-title":"Lancet Oncol"},{"key":"R19-20250504","doi-asserted-by":"crossref","first-page":"3671","DOI":"10.1200\/JCO.21.00334","article-title":"nivolumab versus gemcitabine or pegylated liposomal doxorubicin for patients with platinum-resistant ovarian cancer: open-label, randomized trial in Japan (NINJA).","volume":"39","author":"Hamanishi","year":"2021","journal-title":"J Clin Oncol"},{"key":"R20-20250504","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1093\/annonc\/mdt515","article-title":"Weekly AUC2 carboplatin in acquired platinum-resistant ovarian cancer with or without oral phenoxodiol, a sensitizer of platinum cytotoxicity: the phase III OVATURE multicenter randomized study.","volume":"25","author":"Fotopoulou","year":"2014","journal-title":"Ann Oncol"},{"key":"R21-20250504","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.ygyno.2021.08.032","article-title":"Lurbinectedin versus pegylated liposomal doxorubicin or topotecan in patients with platinum-resistant ovarian cancer: a multicenter, randomized, controlled, open-label phase 3 study (CORAIL).","volume":"163","author":"Gaillard","year":"2021","journal-title":"Gynecol Oncol"},{"key":"R22-20250504","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1111\/1467-9868.00353","article-title":"Bayesian measures of model complexity and fit.","volume":"64","author":"Spiegelhalter","year":"2002","journal-title":"J R Stat Soc Series B Stat Methodol"},{"key":"R23-20250504","doi-asserted-by":"crossref","first-page":"1758835918762094","DOI":"10.1177\/1758835918762094","article-title":"Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?","volume":"10","author":"Lazzari","year":"2018","journal-title":"Ther Adv Med Oncol"},{"key":"R24-20250504","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.semcancer.2020.08.017","article-title":"Challenges for immunotherapy for the treatment of platinum resistant ovarian cancer.","volume":"77","author":"Le Saux","year":"2021","journal-title":"Semin Cancer Biol"},{"key":"R25-20250504","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/s41588-020-0630-5","article-title":"Unraveling tumor-immune heterogeneity in advanced ovarian cancer uncovers immunogenic effect of chemotherapy.","volume":"52","author":"Jim\u00e9nez-S\u00e1nchez","year":"2020","journal-title":"Nat Genet"},{"key":"R26-20250504","doi-asserted-by":"crossref","first-page":"2831","DOI":"10.1158\/1078-0432.CCR-13-3141","article-title":"Molecular pathways: the immunogenic effects of platinum-based chemotherapeutics.","volume":"20","author":"Hato","year":"2014","journal-title":"Clin Cancer Res"},{"key":"R27-20250504","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.canlet.2015.10.002","article-title":"Anthracyclines potentiate anti-tumor immunity: a new opportunity for chemoimmunotherapy.","volume":"369","author":"Zhang","year":"2015","journal-title":"Cancer Lett"},{"key":"R28-20250504","first-page":"e13864","article-title":"Extracellular matrix: a treasure trove in ovarian cancer dissemination and chemotherapeutic resistance.","volume":"13","author":"Valmiki","year":"2021","journal-title":"Cureus"},{"key":"R29-20250504","doi-asserted-by":"crossref","first-page":"853","DOI":"10.2147\/OTT.S335936","article-title":"Immunotherapy in the treatment of platinum-resistant ovarian cancer: current perspectives.","volume":"15","author":"Awada","year":"2022","journal-title":"Onco Targets Ther"},{"key":"R30-20250504","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1186\/s13046-019-1266-0","article-title":"Advances in cancer immunotherapy 2019 - latest trends.","volume":"38","author":"Kruger","year":"2019","journal-title":"J Exp Clin Cancer Res"},{"key":"R31-20250504","doi-asserted-by":"crossref","first-page":"758","DOI":"10.3389\/fcell.2020.00758","article-title":"Tumor microenvironment in ovarian cancer: function and therapeutic strategy.","volume":"8","author":"Yang","year":"2020","journal-title":"Front Cell Dev Biol"},{"key":"R32-20250504","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1186\/s12935-020-01472-9","article-title":"Significance of tumor mutation burden combined with immune infiltrates in the progression and prognosis of ovarian cancer.","volume":"20","author":"Bi","year":"2020","journal-title":"Cancer Cell Int"},{"key":"R33-20250504","doi-asserted-by":"crossref","first-page":"e000147","DOI":"10.1136\/jitc-2019-000147","article-title":"Establishing guidelines to harmonize Tumor Mutational Burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the friends of cancer research TMB harmonization project.","volume":"8","author":"Merino","year":"2020","journal-title":"J Immunother Cancer"},{"key":"R34-20250504","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1038\/s41591-019-0382-x","article-title":"Genomic correlates of response to immune checkpoint blockade.","volume":"25","author":"Keenan","year":"2019","journal-title":"Nat Med"},{"key":"R35-20250504","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13073-018-0605-7","article-title":"Genomics of response to immune checkpoint therapies for cancer: implications for precision medicine.","volume":"10","author":"Conway","year":"2018","journal-title":"Genome Med"},{"key":"R36-20250504","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.tranon.2019.10.010","article-title":"Homologous recombination repair deficiency and the immune response in breast cancer: a literature review.","volume":"13","author":"Pellegrino","year":"2020","journal-title":"Transl Oncol"},{"key":"R37-20250504","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1038\/s41423-020-00565-9","article-title":"Tumor-infiltrating lymphocytes in the immunotherapy era.","volume":"18","author":"Paijens","year":"2020","journal-title":"Cell Mol Immunol"},{"key":"R38-20250504","doi-asserted-by":"crossref","first-page":"364","DOI":"10.3389\/fimmu.2020.00364","article-title":"Characteristics of tumor-infiltrating lymphocytes prior to and during immune checkpoint inhibitor therapy.","volume":"11","author":"Plesca","year":"2020","journal-title":"Front Immunol"},{"key":"R39-20250504","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/s41417-020-0174-y","article-title":"TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.","volume":"27","author":"Choucair","year":"2020","journal-title":"Cancer Gene Ther"},{"key":"R40-20250504","doi-asserted-by":"crossref","first-page":"e126908","DOI":"10.1172\/jci.insight.126908","article-title":"PD-L1 expression and tumor mutational burden are independent biomarkers in most cancers.","volume":"4","author":"Yarchoan","year":"2019","journal-title":"JCI Insight"},{"key":"R41-20250504","doi-asserted-by":"crossref","first-page":"107126","DOI":"10.1016\/j.intimp.2020.107126","article-title":"Association between tumor mutation burden and immune infiltration in ovarian cancer.","volume":"89","author":"Fan","year":"2020","journal-title":"Int Immunopharmacol"},{"key":"R42-20250504","doi-asserted-by":"crossref","first-page":"eaar3593","DOI":"10.1126\/science.aar3593","article-title":"Pan-tumor genomic biomarkers for PD-1 checkpoint blockade\u2013based immunotherapy.","volume":"362","author":"Cristescu","year":"2018","journal-title":"Science"},{"key":"R43-20250504","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.3802\/jgo.2019.30.e105","article-title":"How to use immune checkpoint inhibitor in ovarian cancer?","volume":"30","author":"Park","year":"2019","journal-title":"J Gynecol Oncol"},{"key":"R44-20250504","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s10555-014-9539-8","article-title":"Role of the folate receptor in ovarian cancer treatment: evidence, mechanism, and clinical implications.","volume":"34","author":"Vergote","year":"2015","journal-title":"Cancer Metastasis Rev"},{"key":"R45-20250504","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1158\/1535-7163.MCT-14-1095","article-title":"IMGN853, a folate receptor-alpha (FRalpha)-targeting antibody-drug conjugate, exhibits potent targeted anti-tumor activity against FRalpha-expressing tumors.","volume":"14","author":"Ab","year":"2015","journal-title":"Mol Cancer Ther"},{"key":"R46-20250504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.","volume":"157","author":"O\u2019Malley","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R47-20250504","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11095-023-03649-z","article-title":"Antibody-drug conjugate overview: a state-of-the-art manufacturing process and control strategy.","volume":"41","author":"Li","year":"2024","journal-title":"Pharm Res"},{"key":"R48-20250504","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ygyno.2023.01.020","article-title":"Safety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FR\u03b1)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.","volume":"170","author":"Gilbert","year":"2023","journal-title":"Gynecol Oncol"},{"key":"R49-20250504","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2020.01.037","article-title":"Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRalpha)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer.","author":"O'Malley","year":"2020","journal-title":"Gynecol Oncol"},{"key":"R50-20250504","first-page":"JCO2201900","article-title":"Efficacy and safety of mirvetuximab soravtansine in patients with platinum-resistant ovarian cancer with high folate receptor alpha expression: results from the SORAYA study.","author":"Matulonis","year":"2023","journal-title":"J Clin Oncol"},{"key":"R51-20250504","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1186\/s40425-018-0421-z","article-title":"Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients: nivolumab-related serious\/fatal adverse events.","volume":"6","author":"Zhao","year":"2018","journal-title":"J ImmunoTher Cancer"},{"key":"R52-20250504","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1042\/CS20200308","article-title":"Vascular toxicity associated with anti-angiogenic drugs.","volume":"134","author":"Neves","year":"2020","journal-title":"Clin Sci (Lond)"},{"key":"R53-20250504","doi-asserted-by":"crossref","first-page":"17588359211020529","DOI":"10.1177\/17588359211020529","article-title":"An overview of lurbinectedin as a new second-line treatment option for small cell lung cancer.","volume":"13","author":"Patel","year":"2021","journal-title":"Ther Adv Med Oncol"},{"key":"R54-20250504","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1007\/s00404-020-05865-z","article-title":"The efficacy and toxicity of angiogenesis inhibitors for ovarian cancer: a meta-analysis of randomized controlled trials.","volume":"303","author":"Guo","year":"2021","journal-title":"Arch Gynecol Obstet"},{"key":"R55-20250504","first-page":"1","article-title":"Immune therapy opportunities in ovarian cancer.","volume":"40","author":"Kandalaft","year":"2020","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038183","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,4]],"date-time":"2025-05-04T00:54:59Z","timestamp":1746320099000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000038183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5,24]]},"references-count":55,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000038183","relation":{},"ISSN":["0025-7974","1536-5964"],"issn-type":[{"type":"print","value":"0025-7974"},{"type":"electronic","value":"1536-5964"}],"subject":[],"published":{"date-parts":[[2024,5,24]]}}}